GERN
GERON CORPPrice
Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).
- Feb 25 ▲ Geron Corporation reported strong full-year 2025 financial results w…
- Mar 30 to Mar 30 3 court rulings: 3:25-cv-03356 In re Geron Corporation Derivative Litigation; 3:25-cv-08575 Hyung v. Geron Corporation, et al. and 1 more
- Jul 22 Activist stake: Geron Corporation Reports Inducement Grants Under Nasdaq L…
- Aug 18 Activist stake: Geron Corporation Reports Inducement Grants Under Nasdaq L…
- Sep 18 Activist stake: Geron Corporation Reports Inducement Grants Under Nasdaq L…
- Oct 19 Activist stake: Geron Corporation Reports Inducement Grants Under Nasdaq L…
- Oct 28 ▼ Geron announced the discontinuation of its Phase 3 IMpactMF trial of…
- Oct 28 Trading halt: Halt Resumed: GERN, trading resumed after T3 (News and Res…
- Oct 28 Trading halt: Trading Halt: GERN · T2 (News Released)
- Nov 4 Geron reported Q3 2026 RYTELO net product revenue of $60.1M, up 27%…
- Nov 4 Geron reported Q3 2026 RYTELO net product revenue of $60.1M, beating…
- Nov 4 ▲ Earnings: GERN Q3 2026 Earnings: EPS $0 (+100.0% vs est)
- Nov 16 New insider trade: subscribers see the details Unlock
Signal stack
Where each data set points today.
- InsidersLOCKED
1 open-market trade filed or updated in the last 24 hours. 🔒 Subscribers only.
- InstitutionsBULLISH
Q3 2026: 23 added (0 new), 11 trimmed or exited.
- AnalystsBULLISH
9 of 11 rate it Buy or better. Every target is above the price.
- Short sellersSTEADY
Short interest −10.3% to 66.95M shares. 3.9 days to cover, ≈10.4% of shares.
- TrendDOWNTREND
20% below its 50-day average.
Who's buying
13F· Q3 2026| Fund | Move | Value |
|---|---|---|
| Candriam S.C.A. | ADD | $9.9M |
| PANAGORA ASSET MANAGEMENT INC | ADD | $5.9M |
| Qube Research & Technologies Ltd | TRIM | $2.8M |
| FRANKLIN TEMPLETON INC | DOUBLED | $1.6M |
| Squarepoint Ops LLC | DOUBLED | $1.5M |
| Quadrature Capital Ltd | ADD | $1.2M |
| ALPS ADVISORS INC | ADD | $1.0M |
| Rafferty Asset Management, LLC | ADD | $964.0K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
11 analystsPrice is below the lowest target. Median implies +246%.Targets as of Nov 17, 2026.
| Date | Firm | Rating |
|---|---|---|
| Oct 29, 2026 | Wedbush MAINTAIN | Outperform |
| Oct 28, 2026 | Needham MAINTAIN | Buy |
Insider ledger
Form 4| Insider | Type | Value |
|---|---|---|
| 🔒 Fresh data, subscribers only Nov 16, 2026 | BUY | |
Spiegel Robert J. Director Sep 30, 2026 | AWARD | $7.8K |
Spiegel Robert J. Director Jun 30, 2026 | AWARD | $7.8K |
O'Farrell Elizabeth G. Director May 20, 2026 | AWARD | 220,000 sh |
Molineaux Susan Director May 20, 2026 | AWARD | 220,000 sh |
Spiegel Robert J. Director May 20, 2026 | AWARD | 220,000 sh |
McDonald John F Director May 20, 2026 | AWARD | 220,000 sh |
Bir Dawn Carter Director May 20, 2026 | AWARD | 220,000 sh |
Earnings setup
EstimatesRevision history: 🔒 Fresh data, subscribers only
| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | 🔒 Fresh data, subscribers only | |||
| Next Q | $0.01 | $0.01–$0.01 | No data | $74.5M |
| Current FY | 🔒 Fresh data, subscribers only | |||
| Next FY | $0.09 | $0.09–$0.09 | No data | $338.1M |
Short side
FINRA· Oct 30, 2026| Oct 28, 2026 | Resumption Scheduled | Resumed |
SecBot reports
9 filings · 2 press releases · 1 bullish · 1 bearish · 2 mixed · 5 neutral- NEUTRAL SC 13GNov 10, 2026
State Street Corp filed a Schedule 13G disclosing a passive 5.0% stake in Geron Corp as of…
Monitor for any changes in State Street's position in future 13G filings, but as a passive index/asset manager, this filing is routine and does not signal activist intent. The key catalyst for Geron…
- NEUTRAL INST-CLUSTERNov 6, 2026
Eight institutional investors added $3.6M in GERN positions during Q3 2026, while two trimmed…
The cluster shows conviction from active managers post-earnings, but the IMpactMF trial discontinuation removes a key pipeline catalyst, increasing reliance on LR-MDS. Monitor next quarter's 13F for…
- MIXED 8-KNov 4, 2026
Geron reported Q3 2026 RYTELO net product revenue of $60.1M, up 27% YoY from $47.2M, and achieved…
The discontinuation of IMpactMF removes a major pipeline catalyst and makes Geron a single-product company dependent on LR-MDS. Watch for Q4 2026 revenue trajectory to assess whether the mid-to-high…
- MIXED PRESS-RELEASENov 4, 2026
Geron reported Q3 2026 RYTELO net product revenue of $60.1M, beating the $60.4M consensus by a…
Monitor Q4 2026 revenue trajectory for RYTELO to see if demand growth sustains the 10% QoQ pace; watch for European launch uptake in Germany and France as a second growth leg; the IMpactMF…
All GERN filing & press-release reports (11)
- SC 13G reportNov 10, 2026
- INST-CLUSTER reportNov 6, 2026
- 8-K reportNov 4, 2026
- PRESS-RELEASE reportNov 4, 2026
- 8-K reportOct 28, 2026
- PRESS-RELEASE reportOct 19, 2026
- PRESS-RELEASE reportSep 18, 2026
- PRESS-RELEASE reportApr 22, 2026
- DEFA14A reportApr 7, 2026
- COURT-RULING reportMar 30, 2026
- 8-K reportFeb 25, 2026